Onconic Therapeutics Receives Approval for Phase 2 Clinical Trial Plan of Dual-Inhibitor Targeted Anticancer Drug 'OCN-201' for Ovarian Cancer
[Asia Economy Reporter Lee Gwan-joo] Onconic Therapeutics announced on the 22nd that it has received approval from the Ministry of Food and Drug Safety for the domestic Phase 2 clinical trial plan (IND) of the dual-inhibitory targeted anticancer drug 'OCN-201' (previous development code name JPI-547) for ovarian cancer.
This clinical trial plans to administer OCN-201 to 58 ovarian cancer patients who have experience with PARP (Poly ADP-Ribose Polymerase) inhibitors and show resistance to chemotherapy, in order to explore safety and efficacy. It was selected as a joint development project (NOIU-1402) by the National Cancer Center's Anti-Cancer New Drug and New Treatment Development Project Group and is being conducted with government funding, with clinical trials taking place at nine institutions including the National Cancer Center.
Ovarian cancer is a cancer with almost no symptoms at onset, making early diagnosis difficult and having a high recurrence rate. Previously, chemotherapy was used as the standard treatment for ovarian cancer, but since the introduction of AstraZeneca's Lynparza, a PARP inhibitor new drug, in 2014, several PARP inhibitors have emerged, changing the treatment paradigm for ovarian cancer. As PARP inhibitors have expanded as first-line therapies and health insurance coverage has been applied, the market size continues to grow; however, some patients develop resistance after a certain period of administration.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Iranian Military Spokesperson: "Ceasefire Was an Opportunity to Strengthen Forces... Ready to Respond to War"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Onconic Therapeutics' 'OCN-201' is a dual-inhibitory targeted anticancer drug that simultaneously inhibits PARP and Tankyrase. John Kim, CEO of Onconic Therapeutics, said, “Since safety and some efficacy were confirmed in Phase 1 clinical trials, positive results are expected in this Phase 2 as well,” adding, “We hope to succeed as a next-generation new drug that can overcome the limitations of existing PARP inhibitors and become a new treatment option for ovarian cancer patients suffering from resistance.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
